[ by Ian Le Guillou, Department of Biochemistry, University of Cambridge ]{style=“font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;”} [Although contradictory to the hopes of the Access to Understanding competition, writing about the work described in ]{style=“font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;”}[’NLK is a Novel Therapeutic Target for PTEN Deficient Tumour Cells’]{style=“color: black;